Knight Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CAD 63.81 million compared to CAD 46.07 million a year ago. Net loss was CAD 18.81 million compared to net income of CAD 3.56 million a year ago. Basic loss per share from continuing operations was CAD 0.16 compared to basic earnings per share from continuing operations of CAD 0.03 a year ago. Diluted loss per share from continuing operations was CAD 0.16 compared to diluted earnings per share from continuing operations of CAD 0.03 a year ago.